Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | +5.16% | +5.58% | -37.05% |
04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
04-25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.05% | 564M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac N : Reports Positive Data for COVID-19 Vaccine Candidate